1-9 of 9
Dick Pluim
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer

Rosemarie de Haan, Michel M. van den Heuvel, Judi van Diessen, Heike M.U. Peulen, Erik van Werkhoven, Adrianus J. de Langen, Ferry Lalezari, Dick Pluim, Manon Verwijs-Janssen, Conchita Vens, Jan H.M. Schellens, Neeltje Steeghs, Marcel Verheij, Baukelien van Triest
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (5): 1256–1266.
https://doi.org/10.1158/1078-0432.CCR-20-2551
Published: 01 March 2021
View article titled, Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer
Open the PDF for Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues

Fan Lin, Serena Marchetti, Dick Pluim, Dilek Iusuf, Roberto Mazzanti, Jan H.M. Schellens, Jos H. Beijnen, Olaf van Tellingen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (8): 2084–2095.
https://doi.org/10.1158/1078-0432.CCR-12-3105
Published: 15 April 2013
View article titled, Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues
Open the PDF for Abcc4 Together with Abcb1 and Abcg2 Form a Robust Cooperative Drug Efflux System That Restricts the Brain Entry of Camptothecin Analogues in another window
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

David S. Boss, Wandena S. Siegel-Lakhai, Nadja E. van Egmond-Schoemaker, Dick Pluim, Hilde Rosing, Wim W. ten Bokkel Huinink, Jos H. Beijnen, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4475–4483.
https://doi.org/10.1158/1078-0432.CCR-08-3144
Published: 01 July 2009
View article titled, Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study

Stephan A. Veltkamp, Robert S. Jansen, Sophie Callies, Dick Pluim, Carla M. Visseren-Grul, Hilde Rosing, Susanne Kloeker-Rhoades, Valerie A.M. Andre, Jos H. Beijnen, Christopher A. Slapak, Jan H.M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (11): 3477–3486.
https://doi.org/10.1158/1078-0432.CCR-07-4521
Published: 02 June 2008
View article titled, Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study
Open the PDF for Oral Administration of Gemcitabine in Patients with Refractory Tumors: A Clinical and Pharmacologic Study in another window
Journal Articles

A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

Jeany M. Rademaker-Lakhai, Desiree van den Bongard, Dick Pluim, Jos H. Beijnen, Jan H. M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (11): 3717–3727.
https://doi.org/10.1158/1078-0432.CCR-03-0746
Published: 01 June 2004
View article titled, A Phase I and Pharmacological Study with Imidazolium- <em>trans-</em> DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
Open the PDF for A Phase I and Pharmacological Study with Imidazolium- <em>trans-</em> DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent in another window
Journal Articles

A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors

Jeany M. Rademaker-Lakhai, Catherine Terret, Stephen B. Howell, Christiane M. Baud, Richard F. de Boer, Dick Pluim, Jos H. Beijnen, Jan H. M. Schellens, Jean-Pierre Droz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (10): 3386–3395.
https://doi.org/10.1158/1078-0432.CCR-03-0315
Published: 24 May 2004
View article titled, A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors
Open the PDF for A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors in another window
Journal Articles

Randomized Phase I Clinical and Pharmacologic Study of Weekly versus Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer

Mirjam Crul, Nadja E. Schoemaker, Dick Pluim, Marc Maliepaard, René W. M. Underberg, Margaret Schot, Rolf W. Sparidans, Paul Baas, Jos H. Beijnen, Nico van Zandwijk, Jan H. M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (10): 3526–3533.
Published: 23 September 2003
View article titled, Randomized Phase I Clinical and Pharmacologic Study of Weekly <em>versus</em> Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for Randomized Phase I Clinical and Pharmacologic Study of Weekly <em>versus</em> Twice-Weekly Dose-intensive Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer in another window
Journal Articles

Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin

William C. Zamboni, Anne C. Gervais, Merrill J. Egorin, Jan H. M. Schellens, Deborah R. Hamburger, Brian J. Delauter, Amy Grim, Eleanor G. Zuhowski, Erin Joseph, Dick Pluim, Douglas M. Potter, Julie L. Eiseman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2992–2999.
Published: 01 September 2002
View article titled, Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin
Open the PDF for Inter- and Intratumoral Disposition of Platinum in Solid Tumors after Administration of Cisplatin in another window
Journal Articles

Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins in Vitro Using Non-Substrate Drugs or the BCRP Inhibitor GF120918

Marc Maliepaard, Margôt A. van Gastelen, Akiko Tohgo, Frederick H. Hausheer, Robert C. A. M. van Waardenburg, Laurina A. de Jong, Dick Pluim, Jos H. Beijnen, Jan H. M. Schellens
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (4): 935–941.
Published: 01 April 2001
View article titled, Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins <em>in Vitro</em> Using Non-Substrate Drugs or the BCRP Inhibitor GF120918
Open the PDF for Circumvention of Breast Cancer Resistance Protein (BCRP)-mediated Resistance to Camptothecins <em>in Vitro</em> Using Non-Substrate Drugs or the BCRP Inhibitor GF120918 in another window